Peter Marks On How He Wants To Prepare For The Next Pandemic
Executive Summary
Acknowledging the toll that vaccine opponents have taken on FDA operations, the CBER director emphasizes the need to create stand-by manufacturing capacity, conduct faster studies in special populations, and better understand the mRNA platform.